Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB

Key Takeaways

• AI-driven RWD tools now standard for patient identification
• Early patient input reduces protocol complexity and enrollment delays
• Decentralized trial elements cut site visits, improving retention
• Diversity gaps persist due to geographic and socioeconomic barriers

Pulse Analysis

The recent pauses in Pfizer/BioNTech’s COVID‑19 and Lyme vaccine studies highlight a growing industry pain point: enrollment shortfalls caused by overly rigid protocols. Sponsors are turning to real‑world data (RWD) and electronic health record integration, coupled with AI algorithms, to pinpoint patients who not only meet clinical criteria but also demonstrate a high likelihood of adherence. This shift from reactive recruitment to proactive, data‑driven identification is rapidly becoming the norm, helping to align trial populations with the realities of everyday clinical practice.

Patient engagement has evolved from a peripheral task to a strategic pillar of trial design. By involving patients during protocol development, sponsors can trim unnecessary site visits, simplify procedures, and embed decentralized trial components such as remote monitoring and telehealth. Transparent, ongoing communication—through regular updates, support services, and feedback loops—builds trust and reduces dropout rates. These tactics not only improve the participant experience but also enhance data quality and accelerate timelines, delivering measurable ROI for sponsors.

Despite progress, significant gaps remain. Under‑represented groups continue to face geographic, socioeconomic, and systemic barriers, limiting diversity in enrollment. Data fragmentation across healthcare systems hampers the efficient identification of eligible patients at scale. Moreover, many sponsors still treat recruitment and retention as downstream concerns rather than strategic priorities. Companies that embed patient‑centric planning, leverage integrated RWD platforms, and invest in robust engagement tools are better positioned to close these gaps, streamline operations, and bring therapies to market faster.